Anika Therapeutics Inc. (NASDAQ:ANIK) Q2 2023 Earnings Conference Call August 8, 2023 5:00 AM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard - President and CEO Michael Levitz - EVP, CFO & Treasurer Conference Call Participants George Sellers - Stephens Inc. Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Second Quarter 2023 Earnings Conference Call. [Operator Instructions]. I will now turn the c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction of Inc ...

Anika Therapeutics Inc. (NASDAQ:ANIK) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard - President, CEO & Director Michael Levitz - Executive VP, CFO & Treasurer Conference Call Participants Harrison Parsons - Stephens Mike Petusky - Barrington Research Jim Sidoti - Sidoti Operator Good afternoon, ladies and gentlemen, and welcome to Anika's First Quarter 2023 Earnings Conference Call. [Operator I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 04-3145961 (State or Other Jurisdiction of In ...

SIDOTI VIRTUAL SMALL CAP CONFERENCE MARCH 22, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements w ...

CANACCORD GENUITY MUSCULOSKELETAL CONFERENCE 2023 MARCH 7, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-14027 Anika Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorpor ...

Q4 AND YEAR-END 2022 EARNINGS CALL MARCH 6, 2023 ANIKA. RESTORE ACTIVE LIVING.™ SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company's commercial capabilities, initiatives and production, its product pipeline and associated timelines, its upcoming corporate milestones, and its growth strategy and projections, are forward looking statements wit ...

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President & CEO Mike Levitz - EVP & CFO Conference Call Participants George Sellers - Stephens Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Operator Greetings, and welcome to Anika's Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2022 was $40.3 million, an increase of 2% year-over-year, driven by joint preservation and restoration, and last time buys in non-orthopedic sales [33] - Revenue in the OA Pain Management segment decreased by 2% to $25.7 million due to ordering patterns from J&J Mitek [33] - Adjusted gross margin was 67%, up from 66% in the previous year [34] - Net loss for the quarter was $4.2 million or $0.29 per share, compared to net income of $600,000 or $0.04 per share in Q3 2021 [36] - Adjusted EBITDA was $4.1 million, down from $5.7 million in the same quarter last year [37] Business Line Data and Key Metrics Changes - Joint preservation and restoration revenue increased by 6% to $11.8 million, limited by market dynamics and supply chain challenges [33] - Non-orthopedic revenue increased to $2.8 million compared to $2.2 million last year due to last time buys for certain legacy products [34] - The company continues to benefit from newer products like Tactoset and market-leading HA-based OA pain management solutions [10] Market Data and Key Metrics Changes - The joint preservation market is expected to grow significantly, with the rotator cuff repair market alone valued at nearly $600 million [20] - The company has seen strong international sales, particularly in viscosupplements, which have continued to perform well [10][33] - The overall market dynamics have been impacted by supply chain issues and the recovery of elective procedures, with hip and knee surgeries recovering faster than sports extremity and trauma segments [49] Company Strategy and Development Direction - The company aims to become a global leader in joint preservation, leveraging its OA Pain Management franchise to invest in adjacent high-growth markets [12] - A transformational strategy has expanded the market opportunity from $1 billion to over $8 billion [28] - The company is focused on launching multiple new products, including X-Twist, to drive growth in the joint preservation market [22][43] Management's Comments on Operating Environment and Future Outlook - Management acknowledges ongoing supply chain challenges but expects some relief as they move towards the full release of X-Twist in early 2023 [49] - The company remains optimistic about the joint preservation business despite adjusting growth expectations due to supply chain issues [51] - Management is confident in the differentiated clinical benefits of CINGAL and plans to engage with the FDA regarding U.S. regulatory approval [18][73] Other Important Information - The company has a strong cash position of $87.8 million and no outstanding debt [38] - The company is actively investing in R&D and commercial transformation to support growth objectives [42] - The company has received positive feedback from surgeons regarding new product launches, indicating strong demand [51] Q&A Session Summary Question: What are the underlying macro conditions and supply chain improvements? - Management noted that supply chain issues are prevalent across the market, but they expect some relief as they approach the full release of X-Twist in early 2023 [48] Question: What is the outlook for joint preservation growth? - Management expressed optimism about the joint preservation business, attributing current growth limitations to supply chain issues and indicating strong demand for X-Twist [51] Question: Is there a timetable for meeting with the FDA regarding CINGAL? - Management expects to meet with the FDA in the next few months to discuss the data package for CINGAL [58] Question: Are there mitigation efforts for supply chain issues? - Management confirmed that they are actively working to manage supply chain issues and are confident in meeting demand for the full launch of X-Twist [60] Question: What is the long-term growth outlook for joint preservation? - Management believes that joint preservation can achieve double-digit growth in the long term, supported by new product launches and market opportunities [63]